The potential advantages of liquid biopsy over standard care are real but narrow. It is less invasive than tissue biopsy and can be repeated more frequently, which matters when a lesion is hard to reach or tissue is exhausted. In post-treatment monitoring, it may detect circulating tumour DNA or other molecular signals before anatomical change is visible, and it may reflect multiple sites rather than one sampled area. For high-risk screening, a blood draw is easier to accept than repeated imaging or invasive procedures. But the key word is “potential”: an earlier molecular signal is only useful if there is a pre-specified next step and evidence that acting on it improves outcomes.
The strongest question about unmet need is not “Is this new?” but “What specific deficiency in my current surveillance does this correct?” If the answer is something like “your current imaging misses small-volume recurrence” or “we cannot safely biopsy that area repeatedly,” the liquid biopsy may fill a genuine gap. If the answer is only “more data,” it may add uncertainty rather than reduce it.
For standard care later, ask the specialist to show where the protocol touches your existing schedule. Does it add the blood test while keeping every planned scan, scope, or biopsy? Or does it replace or delay any of them? If it is purely add-on, standard care remains intact. If it replaces anything, ask for the exact interval: a negative liquid biopsy should not be allowed to postpone a scheduled imaging study unless the trial has a written safety rule for that.
Also ask for the off-ramp. If the experimental approach fails or is stopped, is there a defined return to your standard screening or surveillance schedule, and is that return covered by the same health system funding? “Available later” is not enough; you want a protocol that still offers the standard schedule on the same terms.
The opportunity cost is usually hidden in false reassurance and indeterminate results. If a negative liquid biopsy delays a CT or biopsy that would have found something, the delay is the loss. If a positive result triggers repeated scans and eventually a biopsy that finds nothing, the cost is unnecessary procedures and anxiety. Ask what the protocol requires after a positive, negative, or ambiguous result, and how many people in the study are expected to need confirmatory testing. If there is no clear confirmatory pathway for a positive result, that is a red flag.
In practice, the most defensible design is one where liquid biopsy runs alongside standard surveillance, every positive or indeterminate signal is confirmed by tissue or imaging where feasible, and stopping the experimental test simply means continuing the standard programme. If the research option cannot meet those conditions, the safer default is proven surveillance.